Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.

BACKGROUND & AIMS: Integrin αv (ITGAV, CD51) is regarded as a key component in multiple stages of tumor progression. However, the clinical failure of cilengitide, a specific inhibitor targeting surface CD51, suggests the importance of yet-unknown mechanisms by which CD51 promotes tumor progression. METHODS: In this study, we used several hepatocellular carcinoma (HCC) cell lines and murine hepatoma cell lines. To investigate the role of CD51 on HCC progression, we used a 3D invasion assay and in vivo bioluminescence imaging. We used periostin-knockout transgenic mice to uncover the role of the tumor microenvironment on CD51 cleavage. Moreover, we used several clinically relevant HCC models, including patient-derived organoids and patient-derived xenografts, to evaluate the therapeutic efficacy of cilengitide in combination with the γ-secretase inhibitor LY3039478. RESULTS: We found that CD51 could undergo transmembrane cleavage by γ-secretase to produce a functional intracellular domain (CD51-ICD). The cleaved CD51-ICD facilitated HCC invasion and metastasis by promoting the transcription of oxidative phosphorylation-related genes. Furthermore, we identified cancer-associated fibroblast-derived periostin as the major driver of CD51 cleavage. Lastly, we showed that cilengitide-based therapy led to a dramatic therapeutic effect when supplemented with LY3039478 in both patient-derived organoid and xenograft models. CONCLUSIONS: In summary, we revealed previously unrecognized mechanisms by which CD51 is involved in HCC progression and uncovered the underlying cause of cilengitide treatment failure, as well as providing evidence supporting the translational prospects of combined CD51-targeted therapy in the clinic. IMPACT AND IMPLICATIONS: Integrin αv (CD51) is a widely recognized pro-tumoral molecule that plays a crucial role in various stages of tumor progression, making it a promising therapeutic target. However, despite early promising results, cilengitide, a specific antagonist of CD51, failed in a phase III clinical trial. This prompted further investigation into the underlying mechanisms of CD51's effects. This study reveals that the γ-secretase complex directly cleaves CD51 to produce an intracellular domain (CD51-ICD), which functions as a pro-tumoral transcriptional regulator and can bypass the inhibitory effects of cilengitide by entering the nucleus. Furthermore, the localization of CD51 in the nucleus is significantly associated with the prognosis of patients with HCC. These findings provide a theoretical basis for re-evaluating cilengitide in clinical settings and highlight the importance of identifying a more precise patient subpopulation for future clinical trials targeting CD51.

Administration of AG490 decreases the senescence of umbilical cord-mesenchymal stem cells and promotes the cytotherapeutic effect in liver fibrosis.

The therapeutic potential of umbilical cord-mesenchymal stem cell (UC-MSC) transplantation in liver fibrosis has been highlighted. However, the fate of transplanted MSCs in the fibrotic microenvironment remains unclear. In this study, we aim to uncover the fate of transplanted MSCs and develop targeting strategies that could enhance the therapeutic efficacy of MSC therapy in liver fibrosis. We used human UC-MSCs as the study object. For in vitro experiments, we stimulated UC-MSCs with several fibrotic-related factors (Liver fibrotic Factors, LF), including TGFß, TNFα and IFNγ for downstream investigations. We co-cultured LF-treated UC-MSCs with hepatic stellate cell line LX-2 to assess the anti-fibrotic effect. We showed that upon LF stimulation, UC-MSCs exhibited reduced anti-fibrotic activity and underwent rapid senescence. Pathway analysis showed that JAK/STAT3 signaling was highly activated upon LF stimulation, which significantly elevated senescence-associated secretory phenotype (SASP) and senescence in UC-MSCs and could be reversed by a specific JAK inhibitor AG490. Moreover, using both carbon tetrachloride (CCl4) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induce fibrosis models, we demonstrated that AG490 pretreatment promoted UC-MSCs survival within the fibrotic liver microenvironment and exhibited enhance therapeutic efficacy. Overall, we showed that targeting MSC senescence in vivo through AG490 pretreatment could enhance the anti-fibrotic activities of UC-MSCs.

Accelerated electron transfer process via MOF-derived FeCo/C for enhanced degradation of antibiotic contaminants towards heterogeneous electro-Fenton system.

The Fe(III) to Fe(II) process limits the rate of the electro-Fenton system. In this study, MIL-101(Fe) derived porous carbon skeleton-coated FeCo bimetallic catalyst Fe4/Co@PC-700 was prepared as a heterogeneous electro-Fenton (EF) catalytic process. The experimental results showed its good performance in catalytic removal of antibiotic contaminants, the rate constant of tetracycline (TC) degradation catalyzed by Fe4/Co@PC-700 was 8.93 times higher than that of Fe@PC-700 under the pH conditions of raw water (pH = 5.86), exhibited good removal of TC, oxytetracycline (OTC), hygromycin (CTC), chloramphenicol (CAP) and ciprofloxacin (CIP). It was shown that the introduction of Co promoted more Fe0 production, allowing the material to exhibit faster Fe(III)/Fe(II) cycling rates. 1O2 and high-priced metal oxygen species were identified as the main active species of the system, in addition to the analysis of possible degradation pathways and toxicity of intermediates of TC. Finally, the stability and adaptability of Fe4/Co@PC-700 and EF systems to different water matrices were evaluated, showing that Fe4/Co@PC-700 was easy to recover and could be applied to different water matrices. This study provides a reference for the design and system application of heterogeneous EF catalysts.

Cobalt mediated perovskite as efficient Fenton-like catalysts for the tetracycline removal over a neutral condition: The importance of superoxide radical.

Cobalt mediated perovskite oxides (Ca-Fe-Co-x) were prepared for heterogeneous Fenton-like, which exhibited excellent tetracycline (TC) degradation efficiency and wider pH suitability (3-11). Experimental results showed that Ca-Fe-Co-1.0 sample displayed the highest degradation rate could reach 80.5% under neutral conditions, and maintain at around 80% after four cycles. The analysis of degradation mechanism showed that the redox of Fe2+/Fe3+ and Co2+/Co3+ significant enhanced the activation of H2O2 to superoxide radical (∙O2-). Meanwhile, the hydroxyl radical (∙OH) was also detected by ESR analysis. In addition, the possible degradation pathway and mechanism of TC were deduced via UPLC-QTOF/MS analysis and density functional theory (DFT) calculations. The toxicity of TC and its intermediates were also evaluated by the ECOSAR software. The Ca-Fe-Co-1.0/nanocellulose aerogel (NCA) displayed highly removal efficiency of TC wastewater in the long-term operation conduction. This study provided a feasible method to design and synthesis heterogeneous Fenton-like catalysts for antibiotic degradation.

iPSCs-derived mesenchymal stromal cells mitigate anxiety and neuroinflammation in aging female mice.

Perimenopause is a natural transition to menopause, when hormone disturbance can result in both short-term mental disorders, such as anxiety, and long-term neuroinflammation due to blood-brain barrier (BBB) impairment, which may lead to more serious neurological disorders later on, such as dementia. Effective treatments may prevent both short-term and long-term neurological sequela, which formed the aim of this study. In aged female C57BL/6 mice (16-18 months of age), mesenchymal stromal cells (MSCs) differentiated from human-induced pluripotent stem cells (iPSCs), were administered via tail vein injection. Mice showed increased blood estrogen levels, alleviated anxiety and neuroinflammation, and improved BBB integrity. Interestingly, transplanted MSCs were located close to ovarian sympathetic nerves and decreased ovarian norepinephrine levels, which in turn increased ovarian estrogen secretion. Moreover, the administration of anastrozole, an inhibitor of estrogen synthesis, diminished the therapeutic effects of MSCs in vivo, suggesting the effect to be estrogen-dependent. In vitro study confirmed the impact of MSCs on sympathetic nerves via mitochondria exchange. In conclusion, iPSC-derived MSCs may provide a novel option to manage perimenopause-related hormonal dysregulation and neurological disorders during the female aging process.